Get the Stockscreener App
2.715
7.78%
-0.229
After Hours:
2.59
-0.125
-4.60%
Cosciens Biopharma Inc stock is traded at $2.715, with a volume of 5,323.
It is down -7.78% in the last 24 hours and up +0.56% over the past month.
See More
Previous Close:
$2.944
Open:
$2.7994
24h Volume:
5,323
Relative Volume:
0.22
Market Cap:
$8.48M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-11.71%
1M Performance:
+0.56%
6M Performance:
-26.62%
1Y Performance:
+0.00%
1-Day Range:
$2.70
$2.86
1-Week Range:
$2.70
$3.1625
52-Week Range:
$1.96
$6.60
Cosciens Biopharma Inc Stock (CSCI) Company Profile
Compare CSCI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSCI
Cosciens Biopharma Inc
|
2.715 | 8.48M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Cosciens Biopharma Inc Stock (CSCI) Latest News
COSCIENS Biopharma Faces Management Cease Trade Order Amid Filing Delays - TipRanks
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order - The Manila Times
Regulatory Alert: COSCIENS Faces Management Trading Ban Over Missing Financial Reports - Stock Titan
Why COSCIENS Biopharma Inc. (CSCI) Went Down On Thursday? - Insider Monkey
COSCIENS Biopharma flags potential reporting delay By Investing.com - Investing.com Australia
Thursday’s 10 Worst-Performing Stocks - Insider Monkey
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
Sector Update: Health Care Stocks Edge Higher Late Afternoon -March 20, 2025 at 04:02 pm EDT - MarketScreener
Top Midday Decliners -March 20, 2025 at 02:10 pm EDT - Marketscreener.com
COSCIENS Biopharma flags potential reporting delay - Investing.com
COSCIENS Biopharma Faces Potential Delay in Year-End Filings Due to Merger Complexities - TipRanks
Material Control Issues Force COSCIENS to Delay Critical Financial Reports - StockTitan
COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents - The Manila Times
COSCIENS Biopharma Inc. Announces Potential Delay in Annual Financial Filing Due to Audit Complexities - Nasdaq
Cosciens Biopharma announces possible delay in filing 2024-end documents - TipRanks
Material Control Issues Force COSCIENS to Delay Critical Financial Filings Until Q2 - StockTitan
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last We - Asianet Newsable
1 Growth Stock Down 45% to Buy Right Now, According to Wall Street - The Globe and Mail
COSCIENS advances to Phase 2a study for inflammation treatment By Investing.com - Investing.com Australia
CSCI stock touches 52-week low at $2.28 amid market challenges - Investing.com
CSCI stock touches 52-week low at $2.28 amid market challenges By Investing.com - Investing.com South Africa
COSCIENS Biopharma Advances Avenanthramides to Phase 2a Trial - TipRanks
COSCIENS advances to Phase 2a study for inflammation treatment - Investing.com India
Cosciens Biopharma to Start Phase 2a of Inflammation Drug Candidate -March 13, 2025 at 08:21 am EDT - Marketscreener.com
Cosciens Biopharma's early-stage study of anti-inflammatory treatment shows positive results, to start mid-stage study to test efficacy - Marketscreener.com
COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product - The Manila Times
COSCIENS Biopharma Initiates Phase 2a Clinical Efficacy Study for Avenanthramides Product Following Successful Phase 1 Safety Results - Nasdaq
Cosciens Biopharma announces initiation of Phase 2a study for avenanthramides - TipRanks
Septerna pulls lead hypoparathyroidism drug on bilirubin levels - BioWorld Online
COSCIENS Biopharma halts investment in macimorelin; CMO to depart - Seeking Alpha
COSCIENS Biopharma Focuses on Natural Product Growth - TipRanks
Cosciens Biopharma provides update, reiterates pipeline prioritization - TipRanks
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization - GlobeNewswire
COSCIENS Biopharma Discontinues Key Drug Trial, Pivots to Natural Products Pipeline - StockTitan
CSCI stock touches 52-week low at $2.61 amid market challenges - Investing.com Australia
CSCI stock touches 52-week low at $2.61 amid market challenges By Investing.com - Investing.com South Africa
COSCIENS Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
This Biopharma Stock Could Be 2025’s Biggest Comeback Story - Wealth Awesome
Aeterna Zentaris : to Present at Upcoming Biotech Showcase Conference in San Francisco - Marketscreener.com
CSCI stock touches 52-week low at $2.8 amid market challenges - Investing.com Canada
CSCI stock touches 52-week low at $2.8 amid market challenges By Investing.com - Investing.com South Africa
Canada Market's top losers: Draganfly Inc. with 13.78% drop, Digihost Technology Inc, 11.42% - Business Upturn
COSCIENS Biopharma Third Quarter 2024 Earnings: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023) - Yahoo Finance
COSCIENS Biopharma: Q3 Earnings Snapshot - The Pioneer
Cosciens Biopharma Inc Stock (CSCI) Financials Data
There is no financial data for Cosciens Biopharma Inc (CSCI). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):